ICD-10 Coding for B-cell Acute Lymphoblastic Leukemia(C91.00, C91.01, C91.02)
Complete ICD-10-CM coding and documentation guide for B-cell Acute Lymphoblastic Leukemia. Includes clinical validation requirements, documentation requirements, and coding pitfalls.
Also known as:
Related ICD-10 Code Ranges
Complete code families applicable to B-cell Acute Lymphoblastic Leukemia
C91.0-C91.02Primary Range
Acute lymphoblastic leukemia
This range covers all stages and statuses of B-cell acute lymphoblastic leukemia, including active disease, remission, and relapse.
Code Comparison: When to Use Each Code
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C91.00 | Acute lymphoblastic leukemia, not having achieved remission | Use when B-ALL is newly diagnosed or when remission status is not achieved. |
|
| C91.01 | Acute lymphoblastic leukemia, in remission | Use when B-ALL is in remission, confirmed by clinical tests. |
|
| C91.02 | Acute lymphoblastic leukemia, in relapse | Use when B-ALL has relapsed after achieving remission. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information: ICD-10 code for B-cell acute lymphoblastic leukemia
Essential facts and insights about B-cell Acute Lymphoblastic Leukemia
Primary ICD-10-CM Codes for brother cell acute lymphoblastic leukemia
Decision Criteria
clinical Criteria
- Presence of ≥20% blasts in bone marrow biopsy
Applicable To
- New diagnosis of B-ALL
- Persistent disease without remission
Excludes
- T-cell acute lymphoblastic leukemia (C91.10)
Clinical Validation Requirements
- Bone marrow biopsy showing ≥20% blasts
- Immunophenotyping confirming B-cell markers (e.g., CD19, CD79a)
Code-Specific Risks
- Misclassification if remission status is not clearly documented.
Coding Notes
- Ensure documentation specifies B-cell lineage to avoid confusion with T-cell ALL.
C91.01 - Acute lymphoblastic leukemia, in remission
Use when B-ALL is in remission, confirmed by clinical tests.
Applicable To
- B-ALL in remission with ≤5% blasts
Excludes
- Active disease or relapse (C91.00, C91.02)
Clinical Validation Requirements
- Flow cytometry showing ≤5% blasts
- Documentation of remission status
Coding Notes
Ensure remission status is clearly documented in the medical record.
C91.02 - Acute lymphoblastic leukemia, in relapse
Use when B-ALL has relapsed after achieving remission.
Applicable To
- B-ALL in relapse with ≥20% blasts post-treatment
Excludes
- Active disease without prior remission (C91.00)
Clinical Validation Requirements
- Bone marrow biopsy showing ≥20% blasts post-treatment
- Clinical documentation of relapse
Coding Notes
Relapse status must be clearly documented with supporting clinical evidence.
Ancillary Codes
Additional codes that should be used in conjunction with the main diagnosis codes when applicable.
Encounter for antineoplastic immunotherapy
Z51.12Documentation & Coding Risks
Avoid these common documentation and coding issues when documenting B-cell Acute Lymphoblastic Leukemia to ensure proper reimbursement, maintain compliance, and reduce audit risk. These guidelines are particularly important when using ICD-10 code C91.00.
Impact
Clinical: Inaccurate treatment planning and monitoring., Regulatory: Potential non-compliance with coding standards., Financial: Risk of claim denials or incorrect reimbursement.
Mitigation Strategy
Ensure remission status is clearly documented in medical records., Regularly update patient status in clinical notes.
Impact
Reimbursement: Incorrect coding may lead to denied claims or reduced reimbursement., Compliance: Non-compliance with ICD-10 coding guidelines., Data Quality: Inaccurate data reporting and clinical records.
Mitigation Strategy
Use C91.00, C91.01, or C91.02 based on the clinical status of B-ALL.
Impact
Coding remission status inaccurately can lead to audit discrepancies.
Mitigation Strategy
Implement regular training for coders on remission status documentation.
Documentation errors, coding pitfalls, and audit risks are interconnected aspects of medical coding and billing. Addressing all three areas helps ensure accurate coding, optimal reimbursement, and regulatory compliance.
Frequently Asked Questions
Common questions about ICD-10 coding for B-cell Acute Lymphoblastic Leukemia, with expert answers to help guide accurate code selection and documentation.
Documentation Templates for B-cell Acute Lymphoblastic Leukemia
Use these documentation templates to ensure complete and accurate documentation for B-cell Acute Lymphoblastic Leukemia. These templates include all required elements for proper coding and billing.
B-ALL Diagnosis and Treatment
Specialty: OncologyRequired Elements
- Bone marrow biopsy results
- Immunophenotyping details
- Cytogenetic findings
- Remission or relapse status
Example Documentation
Examples: Poor vs. Good Documentation
Poor Documentation Example
Good Documentation Example
Explanation
Need help with ICD-10 coding for B-cell Acute Lymphoblastic Leukemia? Ask your questions below.